The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.62, a high estimate of $41.00, and a low estimate of $17.00. This upward trend is evident, ...
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to ...